Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013 | Zendy

Fabien Diomandé | Zendy; Tènè Marceline Yaméogo | Zendy; Kirsten Vannice | Zendy; MariePierre Préziosi | Zendy; Simonetta Viviani | Zendy; Claude-Roger Ouandaogo | Zendy; Modibo Keita | Zendy; Mamoudou Harouna Djingarey | Zendy; N Mbakuliyemo | Zendy; Bartholomew D. Akanmori | Zendy; Samba O. Sow | Zendy; Patrick Zuber | Zendy

Open Access

Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010–2013

Author(s) -

Fabien Diomandé,

Tènè Marceline Yaméogo,

Kirsten Vannice,

MariePierre Préziosi,

Simonetta Viviani,

Claude-Roger Ouandaogo,

Modibo Keita,

Mamoudou Harouna Djingarey,

N Mbakuliyemo,

Bartholomew D. Akanmori,

Samba O. Sow,

Patrick Zuber

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ599

Subject(s) - medicine , pharmacovigilance , vaccination , meningococcal meningitis , mass vaccination , meningococcal vaccine , vaccine safety , family medicine , clinical trial , pediatrics , adverse effect , virology , immunology , immunization , neisseria meningitidis , antigen , biology , bacteria , genetics

The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis belt countries represented the first introduction of a vaccine specifically designed for this part of the world. During the first year alone, the number of people who received the vaccine through mass vaccination campaigns was several hundredfold higher than that of subjects who participated in the closely monitored clinical trials. Implementation of a system to identify rare but potentially serious vaccine reactions was therefore a high priority in the design and implementation of those campaigns.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research